Abstract 1339
Background
Esophageal squamous cell carcinoma (ESCC), a common gastrointestinal tumor, is listed as the sixth leading cause of cancer-related death worldwide, with high morbidity and mortality as its important characteristics. In recent years, despite advances in diagnosis and treatment of ESCC, the mortality rate of ESCC is still very high, with an average overall 5-year survival rate of about 10% ∼ 41%.As with many other solid tumors, development and progression of ESCC are also considered gene regulatory disorders caused by oncogene activation and inactivation accumulation and disorders of tumor suppressor genes (TSG). Therefore, screening and exploring the key gene proteins for the occurrence, development, treatment and clinical prognosis of ESCC is an important topic in the field of ESCC research at present.
Methods
Reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemical (IHC) staining were employed to determine IBSP expression at the mRNA and protein levels in clinical ESCC samples. Moreover, functional studies were adopted to study the tumor-promoter function of IBSP.
Results
IBSP up-regulation was found in 21 of 45 (46.7%) primary ESCC cells at mRNA level by transcription-polymerase chain reaction (RT-PCR). In addition, IHC staining further demonstrated that IBSP was up-regulated in ESCC cases and up-regulation of IBSP protein was significantly relevant to lymph node metastasis (P = 0.017), clinicopathologic stage (P = 0.001) and poor disease survival (P = 0.000) of ESCC patients. Moreover, functional studies illustrated that IBSP gene can promote the ability of proliferation and metastasis of ESCC cells. Furthermore, it was found that IBSP can regulate the EMT process by regulating MMP2 gene and N-cadherin, which promotes the metastasis of tumor cells.
Conclusions
the results of this study showed that IBSP up-regulation was often found in ESCC tumor specimens, indicating poor prognosis of ESCC patients. Moreover, it also demonstrated that IBSP could improve the ability of ESCC cell proliferation and tumor metastasis, which may be a valuable prognostic indicator in ESCC patients. Yet, the mechanism by which IBSP promotes tumorigenesis and development needs more researches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2066 - Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first line (1L) immuno-oncology (IO) monotherapy (mono tx)
Presenter: Denis Talbot
Session: Poster Display session 1
Resources:
Abstract
5919 - Real-world effectiveness of nivolumab monotherapy after prior systemic therapy in advanced non-small cell lung cancer (NSCLC) in the United States
Presenter: David Stenehjem
Session: Poster Display session 1
Resources:
Abstract
3368 - Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population
Presenter: Nikolaj Frost
Session: Poster Display session 1
Resources:
Abstract
3775 - Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster Display session 1
Resources:
Abstract
3926 - Impact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: a REAL-Oncology analysis from the I-O Optimise initiative
Presenter: Michael Snee
Session: Poster Display session 1
Resources:
Abstract
5068 - First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
Presenter: Karim Amrane
Session: Poster Display session 1
Resources:
Abstract
1182 - Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small-cell lung cancer patients
Presenter: Teppei Sugano
Session: Poster Display session 1
Resources:
Abstract
2297 - Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)
Presenter: Yosuke Kawashima
Session: Poster Display session 1
Resources:
Abstract
2739 - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Presenter: Christian Grohe
Session: Poster Display session 1
Resources:
Abstract
1357 - Upfront atezolizumab chemoimmunotherapy-associated Immune-related adverse events in patients with advanced non-small cell lung cancer
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract